Summary
Cisplatin-based multiple-drug chemotherapy is currently considered to be the most effective treatment for advanced and metastatic urothelial cancers. The combination of cisplatin, methotrexate and vinblastine (CMV) has been used at our institution for neoadjuvant and adjuvant chemotherapy. A complete response rate of 50% has been achieved in 28 evaluable patients with metastatic or locally advanced transitional cell carcinoma treated according to a neoadjuvant protocol. Our impression, based on early data, is that adjuvant CMV can effect at least a delay in disease progression, and possibly a prolonged disease-free survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, McWhirter KM, Torti FM (1985) Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A northern California oncology group study. J Clin Oncol 3:1463–1470
Scher HI, Yagoda A, Herr HW, Sternberg CN, Bosi G, Morse MJ, Sogani PC, Watson RC, Dershaw DD, Renter V, Geller N, Hollander PS, Vaughan ED, Whitmore WF, Jr, Fair WR (1988) Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 139:470–474
Scher HI, Yagoda A, Herr HW, Sternberg CN, Morse MJ, Sogani PC, Watson RC, Reuter V, Whitmore WF, Fair WR (1988) Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors. J Urol 139:475–477
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Freiha, F., de Vries, C. & Torti, F. Neoadjuvant and adjuvant chemotherapy of transitional cell carcinoma of the urothelium with cisplatin, methotrexate and vinblastine. World J Urol 6, 153–157 (1988). https://doi.org/10.1007/BF00326792
Issue Date:
DOI: https://doi.org/10.1007/BF00326792